Share this link via:
The global brigatinib tablets market size was valued at USD 1.15 billion in 2025 and is projected to reach USD 1.28 billion in 2026, expanding to USD 2.38 billion by 2034, growing at a CAGR of 9.4% during the forecast period (2026-2034).
Brigatinib is a breakthrough next-generation anaplastic lymphoma kinase (ALK) inhibitor specifically designed to address the clinical shortcomings of first-generation ALK inhibitors with its distinctive dimethylphosphine oxide (DMPO) pharmacophore structure, which is engineered for superior binding affinity to the ALK kinase domain, enhanced blood-brain barrier penetration and retained inhibitory activity against a broad range of resistance mutations observed following crizotinib, ceritinib and other first-generation ALK inhibitors. Brigatinib was originally developed by ARIAD Pharmaceuticals, and was later acquired by Takeda Pharmaceutical Company. Brigatinib was approved by the FDA in 2017 for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) patients who have progressed on, or have been intolerant to, crizotinib, and full approval came after the pivotal ALTA-1L Phase III trial, which showed an improvement in progression-free survival (PFS) compared to crizotinib in treatment-naive patients.
Beyond the standard ability to inhibit ALK, the drug also has high activity against ROS1 rearrangements and selected EGFR mutations, as well as against over 17 mutations known to cause resistance to second-generation ALK inhibitors, including the difficult-to-treat G1202R solvent-front mutation, the most common mechanism of resistance to these drugs. The wide kinase inhibition profile makes brigatinib a versatile therapeutic platform that may help patients navigate multiple lines of treatment, enabling continued utilization of the drug along the treatment path and providing ongoing revenues per patient.
The clinical rationale for the adoption of brigatinib is extremely strong, and it is based on its remarkable efficacy in the central nervous system, which is the most important unmet need in ALK-positive NSCLC where brain metastases occur in 30-40% of the patients at diagnosis and in most patients during disease progression. In patients with measurable brain metastases, intracranial objective response was achieved in 78% of those treated with brigatinib compared to 26% of those receiving crizotinib, while 38% of patients with existing or high risk of CNS involvement achieved complete intracranial response with brigatinib versus 8% with crizotinib, making brigatinib the preferred treatment option for these patients.
| Report Coverage | Details |
|---|---|
| Base Year | 2025 |
| Base Year Value | USD 1.15 Billion |
| Forecast Value | USD 2.38 Billion |
| CAGR | 9.4% |
| Forecast Period | 2025-2034 |
| Historical Data | 2022-2025 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | By Indication, Line of Therapy, Dosage Strength, Distribution Channel, End-User |
| Region Covered | North America, Europe, Asia Pacific, Middle East & Africa, Latin America |
| Countries Covered | US, Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, UAE, Saudi Arabia |
| Key Market Playes | Takeda Pharmaceutical Company, Pfizer Inc., Roche, Novartis AG, Bristol Myers Squibb |
Get more details on this report - Request Free Sample
The key factor driving market growth in the brigatinib market is the steady increase in the size of the identifiable population of patients with ALK-positivity, driven by the broad use of next-generation sequencing and detailed genomic profiling as standard practice in the oncology community, shifting the detection of ALK rearrangement from specialized academic centers to the community oncology setting. The theoretical population of non-small cell lung cancer (NSCLC) patients treated with ALK inhibitors in the major markets is estimated to be approximately 75,000 to 100,000 per year, while the actual population was limited by the lack of availability of molecular testing, suggesting a significant gap in actual treated population versus the theoretical population.
Multiplex NGS panels have been introduced into routine diagnostic workflow, resulting in a significant increase in the identification rates of ALK rearrangement, well above 85-90% across developed markets and quickly gaining adoption in emerging healthcare systems, via centralized reference laboratory networks and international access programs. This diagnostic evolution directly increases the therapeutic funnel for brigatinib in all treatment lines, and liquid biopsy technologies allow the molecular profiling of patients in a non-invasive way, bypassing the tissue access hurdle and allowing serial monitoring of resistance during treatment.
Patients with ALK-positive non-small cell lung cancer are relatively younger with light or never smoking backgrounds and adenocarcinoma histology, which are the characteristics that allow patients to tolerate longer treatment duration and have prolonged survival, leading to significant therapeutic value due to lifetime treatment duration averaging 18-24 months/line of therapy.
The most important clinical advantage driving brigatinib adoption is its superior intracranial activity, which has the potential to solve the greatest problem in the treatment of ALK-positive Nsclc, which is brain metastases, which account for many treatment failures and significant morbidity in the disease. The blood-brain barrier is a natural barrier that prevents systemic therapy from penetrating and causes sanctuary areas for tumor progression that have traditionally needed radiation therapy and neurocognitive side effects and reduced quality of life.
Brigatinib's molecular engineering is designed to optimize its physicochemical properties for improved CNS penetration, resulting in high CSF levels with therapeutic activity against CNS disease. Clinical validation in ALTA-1L showed brigatinib's median PFS was 24.0 months vs 11.0 months for crizotinib, with 89% of patients sustaining PFS vs 72% for crizotinib, resulting in a change in treatment paradigm from the onset of brain metastases to prevention.
A significant barrier to market expansion for brigatinib is the competitive pressure from lorlatinib, a third-generation macrocyclic ALK inhibitor that provides more comprehensive mutation resistance cover as well as better delivery to the central nervous system which has demonstrated remarkable success in the CROWN Phase III trial with 5-year progression-free survival rates of 60% compared to 8% for crizotinib.The mechanism of action of lorlatinib is different from brigatinib, which allows it to overcome all known ALK resistance mutations, including G1202R, the most common resistance mechanism for brigatinib, and therefore poses a competitive displacement risk both in first-line and sequential therapy.
As the landscape of treatment changes, lorlatinib is likely to become the preferred first-line treatment for patients with high-risk disease characteristics, such as brain metastases and high tumor burden, while brigatinib may have a more limited role in treatment-naïve patients, and may be less useful in post-progression settings where lorlatinib offers a better resistance profile.
The greatest transformational market opportunity would be the potential use of brigatinib in the adjuvant treatment of patients with stage I and II ALK-positive non-small cell lung cancers after undergoing complete tumor resection, in which the groundbreaking success of targeted agents in EGFR-mutant disease via the ADAURA study trial has set a precedent in the use of kinase inhibitors to prevent recurrence in molecularly selected patients. Adjuvant clinical trials with brigatinib may show improvements in disease-free survival in comparison with conventional chemotherapy, allowing market growth beyond metastatic disease to include curative therapy.
Adjuvant treatment opportunities often entail multiyear and fixed course treatments among healthier patient pools able to endure long-term drug regimens, thereby opening huge market potential with per-patient values far surpassing those from metastatic disease markets due to increased longevity.
A significant growth opportunity lies in the development of rational combination therapies for the drug brigatinib in combination with other targeted drugs such as MEK inhibitors, heat shock protein 90 inhibitors, anti-angiogenics, or immune checkpoint inhibitors, to combat resistance mechanisms and prolong treatment efficacy beyond the ability of single-agent therapy. This is driven by the need to inhibit the bypass signals that are generated after ALK signaling such as EGFR upregulation and MET amplification.
Validation of combination approaches will allow a company to pursue a premium pricing approach for their drug while also prolonging the course of treatment for each individual patient due to increased efficacy and slower resistance build-up.
One transformational development associated with changing brigatinib use includes the incorporation of circulating tumor DNA testing into clinical practice in order to monitor resistance mutations on a continual basis and optimize the sequencing strategy of therapies, which would allow oncologists to identify the appearance of ALK resistance mutations well before imaging changes, thus allowing for adjustment of treatment by way of increasing dosage, implementing combination treatments, and altering treatments according to the genetic changes.
Liquid biopsy-guided treatment algorithms are increasingly being adopted in academic medical centers and comprehensive cancer programs, presenting new avenues for brigatinib usage in molecularly selected patient populations by serial testing rather than progression-driven approaches.
The advancement in the development of dosing techniques and proactive measures to counteract adverse effects has improved the tolerance and continuation of brigatinib through the implementation of patient-specific models of pharmacy care, drug monitoring and early-intervention monitoring plans, which prevent early onset of pulmonary complications without compromising its efficacy. Such efforts improve treatment adherence and persistence, supporting market growth.
North America will lead in terms of market size, reaching USD 540 million in 2025, which is expected to grow with an 8.8% CAGR during the forecast period until 2034 due to advanced cancer healthcare facilities, increased use of next generation sequencing as standard of care, and reimbursement policies through insurance coverages under commercial insurance companies and Medicare, enabling higher prices. The U.S. accounts for 87% of North American revenues due to efficient specialty pharmacy networks in handling prior authorizations and providing patient support services.
The prevalence of highly skilled thoracic oncologists and centers of excellence in cancer contributes to the rapid adoption of novel treatment protocols along with providing evidence that sustains the guidelines adherence and insurance reimbursement for therapies. Oncologist awareness of the disease and well-developed networks of patient advocacy groups guarantee proper utilization of the molecular tests.
The Asia Pacific region is the fastest-growing market with expected compound annual growth rate of 11.2% to reach a market size of USD 485 million by 2025, due to higher incidence of ALK rearrangements among Asians, where the prevalence of ALK rearrangements is 5–7%, compared with 3–5% in Western populations. as opposed to only 3-5% in western regions. China was identified as the driving market for the growth of the region because of the inclusion of Brigatinib into national reimbursement drug list after negotiations lowered prices by about 60-70%.
Japan and South Korea have well-established secondary markets with molecular testing infrastructure and good reimbursement environment, whereas the Southeast Asian markets indicate increasing adoption with development of health care infrastructure and insurance coverage.
First-Line Treatment is leading with 58% market share worth USD 667 million in 2025, registering a 10.1% CAGR during 2025–2034 due to FDA approval based on ALTA-1L clinical trials and guidelines recommending it as an ideal initial treatment of ALK positive metastatic non-small cell lung cancer. First-Line Treatment enjoys the benefit of long-term treatment spanning over 24 months and healthy patient population.
Second-Line Treatment accounts for 32% of the market share valued at USD 368 million in 2025, including ALK-positive patients who have failed on crizotinib or any other first-line treatment, which is where brigatinib has demonstrated strong efficacy by showing success against different resistance mutations. Third Line & Beyond will capture 10% market share targeting heavily pretreated patients with complex resistance mechanisms.
180 mg tablets have a market share of 65% valued at USD 748 million in 2025 these tablets are used for maintenance of dosage after the titration process and contribute most of the revenue from continuous treatments due to the usage of the drug daily for the duration of treatment. 90 mg tablets are 28% of the total market share and are used as an initial dose for maintenance in patients who require dose adjustments due to toxic side effects.
The Specialty Pharmacies segment is the most dominant, having a 58% share valued at USD 667 million in 2025, owing to the advantage of oral route of administration which makes it feasible to dispense in an outpatient setting via oncology-specific pharmacy chains that provide complete patient support services. Hospital pharmacies and retail & online pharmacies account for 28% and 14% of the market, respectively.
The global brigatinib tablets market is situated in the highly competitive environment of ALK inhibitors, where Takeda Pharmaceutical has exclusive rights for brigatinib commercialization amidst competitors like alectinib, lorlatinib, crizotinib, and ceritinib. Competitive positioning revolves around clinical superiority, especially in terms of brain penetration, resistance mutation coverage, and actual safety records, along with extensive educational campaigns for physicians and patients.
Takeda’s competitive strategy includes generating real-world evidence, participation in post-marketing trials, and collaborations with specialty pharmacy networks that will ensure access to brigatinib among different healthcare systems.
April 2026: Takeda announced the initiation of the Phase III ALTA-ADJ trial in which brigatinib is being compared to placebo in early-stage, completely resected ALK-positive non-small cell lung cancer patients, thus indicating a possible market growth for a curative indication setting.
February 2026: Follow-up data up to 6 years from the ALTA-1L study presented at the World Conference on Lung Cancer showed sustained progression-free survival benefits from brigatinib, with median overall survival not yet reached among brigatinib-treated patients.
December 2025: The updated prescribing information for brigatinib, which included improved recommendations for the treatment of patients with early-onset pulmonary adverse events, received an endorsement from the European Medicines Agency.
October 2025: A real-world evidence analysis conducted using the Flatiron Health oncology database established the efficacy of brigatinib as observed in clinical trials.
You'll get the sample you asked for by email. Remember to check your spam folder as well. If you have any further questions or require additional assistance, feel free to let us know via-
+1 724 648 0810 +91 976 407 9503 sales@intellectualmarketinsights.com
01 Jul 2026
Intellectual Market Insights Research © 2026. All rights reserved.
